ArticleMaterials (Basel, Switzerland)2026
Comparative Effects of Fischer-Tropsch Waxes with Different Carbon-Chain Ranges on Warm-Mix Asphalt Performance: An Experimental and Molecular Dynamics Simulation Study.
Article in Materials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Fischer-Tropsch (FT) wax is widely used as an organic warm-mix asphalt (WMA) additive, lowering binder viscosity during construction while improving high-temperature deformation resistance in service; however, the comparative responses of SBS-modified asphalt to different FT wax grades remain insufficiently understood. Sasobit and three FT waxes with different carbon-chain ranges (FT 80, FT 90, FT 100) were incorporated into SBS-modified asphalt at about 7.0 wt%, and their effects on macroscopic performance, rheology, molecular packing, and diffusion were evaluated using physical-property tests, rotational viscosity, dynamic shear rheometer (DSR) testing, and molecular dynamics (MD) simulation. In the MD analysis, the wax additives were represented by linear alkane molecules with different chain lengths, and the systems were subjected to structural optimization, annealing, and NPT equilibration using the COMPASS III force field before the molecular descriptors were evaluated. The experimental results showed that all four additives produced a trade-off between increased high-temperature stiffness and reduced low-temperature ductility. Sasobit gave the strongest viscosity reduction (>70% above 165 °C), while FT 90 and FT 100 showed more stable, predictable viscosity-temperature behavior favorable for a wider construction window. DSR results showed higher complex modulus and lower phase angle for all modified binders at low frequencies, suggesting an increased elastic contribution and greater resistance to deformation under the tested rheological conditions; FT 80 produced the greatest stiffening but also the largest free volume and loosest molecular packing, whereas FT 100 increased cohesive energy density and reduced free volume, reflecting denser packing and stronger intermolecular cohesion. MD simulations revealed that FT wax enhanced short-time local molecular mobility and segment diffusion in its molten state (explaining the warm-mix viscosity reduction), whereas macroscopic stiffening and ductility loss at ambient temperatures were dictated by wax microcrystallization and physical network constraints that restricted long-range chain relaxation. By comparing three FT wax grades and Sasobit under the same experimental dosage and testing framework, this study provides a controlled assessment of the relationships among wax-grade characteristics, binder-scale rheological responses, and MD-derived molecular descriptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.